Correction to: Nature Cancer https://doi.org/10.1038/s43018-022-00400-2, published online 4 July 2022.
In the version of this article initially published, in the first sentence of the second paragraph now reading “Niraparib is a PARP-1/2 inhibitor approved for recurrent or advanced ovarian cancers,” the word “endometrial” originally appeared in place of “ovarian”. The error has been corrected in the HTML and PDF versions of the article.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Spring, L.M., Han, H., Liu, M.C. et al. Author Correction: Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancer. Nat Cancer 3, 1138 (2022). https://doi.org/10.1038/s43018-022-00430-w
Published:
Issue Date:
DOI: https://doi.org/10.1038/s43018-022-00430-w
